Imugene
Update in progressIMU.AX (ASX)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Imugene Limited, based in Sydney, is a clinical-stage immuno-oncology company developing therapies to stimulate anti-tumour immunity. Its lead program azer-cel is an allogeneic CAR-T in Phase 1 for relapsed/refractory NHL and B-ALL. Other programs include CF33 VAXINIA, CF33 CD19 CAR-T, and CF33 oncolytic virotherapy for solid tumours; HER-Vaxx (Phase 2); HERIZON (Phase 1b/2); PD1-Vaxx (Phase 2); and NeoPOLEM (Phase 2).
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section